Sign in

    Zegbeh Jallah

    Research Analyst at Roth Capital Partners

    Zegbeh Jallah is Managing Director and Senior Research Analyst in Biotechnology at Roth Capital Partners, specializing in SMID cap biotechnology companies. She covers firms such as IDEAYA Biosciences and contributes in-depth research across the biotech sector, with a strong focus on clinical-stage and innovative therapeutic companies. Jallah joined Roth Capital Partners in August 2019, after a career focused on equity research and healthcare analysis, and she holds a Ph.D. in a related discipline. Her professional credentials include Director-level research responsibilities and a presence at major industry conferences.

    Zegbeh Jallah's questions to IDEAYA Biosciences (IDYA) leadership

    Zegbeh Jallah's questions to IDEAYA Biosciences (IDYA) leadership • Q1 2022

    Question

    Zegbeh Jallah followed up on the correlation between SDMA reduction and tumor response, asking about patient variability and whether clinical combination data might be available to influence GSK's decision.

    Answer

    Chief Scientific Officer Michael White reiterated that preclinical data suggests getting below a threshold of SDMA is key, rather than the percentage change. CEO & President Yujiro Hata noted that clinical tumor PD data is still limited for assessing variability and confirmed that clinical combination data is not a requirement for the GSK option package.

    Ask Fintool Equity Research AI